{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T09:22:21Z","timestamp":1754558541621,"version":"3.37.3"},"reference-count":91,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006692","name":"University of Turin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.semradonc.2024.07.013","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T06:03:18Z","timestamp":1733983398000},"page":"16-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advanced Stage Hodgkin and Diffuse Large B-Cell Lymphomas: Is There Still a Role for Consolidation Radiotherapy in the PET Era?"],"prefix":"10.1016","volume":"35","author":[{"given":"Mario","family":"Levis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.semradonc.2024.07.013_bib0001","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1056\/NEJMe2207639","article-title":"A better treatment for advanced-stage Hodgkin's lymphoma?","volume":"387","author":"Longo","year":"2022","journal-title":"N Engl J Med"},{"issue":"S1","key":"10.1016\/j.semradonc.2024.07.013_bib0002","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/hon.3140","article-title":"Are we reaching the maximum cure rate for Hodgkin lymphoma?","volume":"41","author":"Johnson","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0003","first-page":"51","article-title":"Current frontline treatment of diffuse large B-cell lymphoma","volume":"36","author":"Spinner","year":"2022","journal-title":"Oncology"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0004","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.semradonc.2024.07.013_bib0005","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin's Lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0006","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.semradonc.2024.07.013_bib0007","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","article-title":"Risk of heart failure in survivors of Hodgkin lymphoma: Effects of cardiac exposure to radiation and anthracyclines","volume":"129","author":"van Nimwegen","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0008","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S2352-3026(15)00153-2","article-title":"Cardiovascular disease after treatment for Hodgkin's lymphoma: An analysis of nine collaborative EORTC-LYSA trials","volume":"2","author":"Maraldo","year":"2015","journal-title":"Lancet Hematol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0009","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S2352-3026(22)00082-5","article-title":"An Integrated approach to cardioprotection","volume":"9","author":"Maraldo","year":"2022","journal-title":"Lancet Hematol"},{"issue":"8","key":"10.1016\/j.semradonc.2024.07.013_bib0010","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/annonc\/mdt156","article-title":"Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma","volume":"24","author":"Maraldo","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0011","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.radonc.2019.05.009","article-title":"Inclusion of heart substructures in the optimization process of volumetric modulated arc therapy techniques may reduce the risk of heart disease in Hodgkin's lymphoma patients","volume":"138","author":"Levis","year":"2019","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2024.07.013_bib0012","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.radonc.2018.08.017","article-title":"Comparison of butterfly volumetric modulated arc therapy to full arc with or without deep inspiration breath hold for the treatment of mediastinal lymphoma","volume":"129","author":"Starke","year":"2018","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2024.07.013_bib0013","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijrobp.2011.12.034","article-title":"Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma","volume":"84","author":"Hoppe","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2024.07.013_bib0014","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.radonc.2017.07.033","article-title":"Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: The impact of proton therapy and\/or deep inspiration breath hold","volume":"125","author":"Rechner","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0015","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.2147\/OTT.S220730","article-title":"Proton therapy for lymphomas: current state of the art","volume":"12","author":"Ricardi","year":"2019","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0016","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.prro.2020.06.005","article-title":"Adoption of expansion margins to re- duce the dose received by the coronary arteries and the risk of cardiovascular events in lymphoma patients","volume":"11","author":"De Luca","year":"2021","journal-title":"Pract Radiat Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2024.07.013_bib0017","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ijrobp.2023.05.011","article-title":"A quality control study on involved node radiation therapy in the European organisation for research and treatment of cancer\/lymphoma study association\/fondazione italiana linfomi H10 trial on stages I and II Hodgkin lymphoma: Lessons learned","volume":"117","author":"Aleman","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.semradonc.2024.07.013_bib0018","article-title":"Radiation therapy in the German Hodgkin tudy group HD 16 and HD 17 trials: quality assurance and dosimetric analysis for Hodgkin lymphoma in the modern era","volume":"8","author":"Oertel","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1183906","article-title":"Radiation dose to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma- a risk stratified analysis of the GHSG HD17 trial","volume":"13","author":"Oertel","year":"2023","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2024.07.013_bib0020","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0021","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","article-title":"Modern radiation therapy for nodal non-Hodgkin lymphoma \u2013 target definition and dose guidelines from the international lymphoma radiation oncology group","volume":"89","author":"Illidge","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0022","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","article-title":"Proton therapy for adults with mediastinal lymphomas: The International Lymphoma Radiation Oncology Group guidelines","volume":"132","author":"Dabaja","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0023","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13014-020-01504-8","article-title":"Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin's lymphoma involving the mediastinum","volume":"15","author":"Filippi","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0024","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijrobp.2018.01.011","article-title":"The role of radiation therapy in patients with relapsed or refractory Hodgkin Lymphoma: Guidelines from the international lymphoma radiation oncology group","volume":"100","author":"Constine","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0025","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.clml.2016.09.008","article-title":"Potential benefit of involved-field radiotherapy for patients with relapsed-refractory Hodgkin's lym- phoma with incomplete response before autologous stem cell trans- plantation","volume":"17","author":"Levis","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.semradonc.2024.07.013_bib0026","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ijrobp.2023.02.019","article-title":"Peritransplant radiation therapy in patients with refractory or relapsed Hodgkin lymphoma undergoing autologous stem cell transplant: Long-term results of a retrospective study of the Fondazione Italiana Linfomi","volume":"116","author":"Levis","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0027","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ijrobp.2022.12.017","article-title":"Don't put the CART before the horse: The role of radiation therapy in Peri-CAR T-cell therapy for aggressive B-cell non-Hodgkin lymphoma","volume":"116","author":"Saifi","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0028","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.3324\/haematol.2023.283311","article-title":"Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma","volume":"108","author":"Saifi","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0029","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: Consensus of the international conference on malignant lymphomas imaging working group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0030","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0031","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijrobp.2019.02.001","article-title":"The optimal use of imaging in radiation therapy for lymphoma: Guidelines from the international lymhpoma radiation oncology group (ILROG)","volume":"104","author":"Mikhaeel","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"24","key":"10.1016\/j.semradonc.2024.07.013_bib0032","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa022628","article-title":"European organization for research and treatment of cancer lymphoma group. Involved-field radiotherapy for advanced Hodgkin's lymphoma","volume":"348","author":"Aleman","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semradonc.2024.07.013_bib0033","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1200\/JCO.2004.01.021","article-title":"Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need?","volume":"22","author":"Laskar","year":"2004","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.semradonc.2024.07.013_bib0034","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.2009.26.0323","article-title":"Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: Survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519)","volume":"28","author":"Johnson","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2024.07.013_bib0035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijrobp.2006.08.041","article-title":"European organization for research and treatment of cancer (EORTC) lymphoma group. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma","volume":"67","author":"Aleman","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"32","key":"10.1016\/j.semradonc.2024.07.013_bib0036","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1200\/JCO.2010.33.9549","volume":"29","author":"Borchmann","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0037","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","volume":"107","author":"Hutchings","year":"2006","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.semradonc.2024.07.013_bib0038","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0039","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomized, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.semradonc.2024.07.013_bib0040","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","article-title":"Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin Lymphoma: Final results of the phase II part of the HD0801 study","volume":"34","author":"Zinzani","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2024.07.013_bib0041","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","volume":"36","author":"Gallamini","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.semradonc.2024.07.013_bib0042","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US intergroup trial of response-adapted therapy for stage III to IV Hodgkin Lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: southwest oncology group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.semradonc.2024.07.013_bib0043","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.semradonc.2024.07.013_bib0044","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S1470-2045(17)30103-1","volume":"18","author":"Borchmann","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9828","key":"10.1016\/j.semradonc.2024.07.013_bib0045","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0046","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1080\/10428194.2021.1881515","article-title":"Advanced-stage Hodgkin lymphoma: have effective therapy and modern imaging changed the significance of bulky disease?","volume":"62","author":"Milgrom","year":"2021","journal-title":"Leukemia Lymphoma"},{"issue":"33","key":"10.1016\/j.semradonc.2024.07.013_bib0047","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1200\/JCO.20.00935","article-title":"Consolidation radiotherapy could be safely omitted in advanced Hodgkin Lymphoma with large nodal mass in complete metabolic response after ABVD: Final analysis of the randomized GITIL\/FIL HD0607 trial","volume":"38","author":"Gallamini","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0048","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1182\/bloodadvances.2021005150","article-title":"Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: Final results of FIL HD0801 trial","volume":"5","author":"Ricardi","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.semradonc.2024.07.013_bib0049","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3324\/haematol.2016.141846","article-title":"Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography er: Prognostic significance of measurements in the coronal ant transverse planes","volume":"101","author":"Kumar","year":"2016","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.semradonc.2024.07.013_bib0050","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/bloodadvances.2019001265","article-title":"Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease","volume":"4","author":"Qi","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.semradonc.2024.07.013_bib0051","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00277-019-03889-3","article-title":"Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08- 01 FIL study","volume":"99","author":"Rigacci","year":"2020","journal-title":"Ann Hematol"},{"issue":"S1","key":"10.1016\/j.semradonc.2024.07.013_bib0052","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/hon.3163_4","article-title":"Frontline intensified ABVD demonstrates superior efficacy than PET-adapted ABVD in advanced Hodgkin lymphoma: Th FIL-rouge phase 3 trial by the Fondazione Italiana Linfomi","volume":"41","author":"Pinto","year":"2023","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2024.07.013_bib0053","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.semradonc.2024.07.013_bib0054","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with Brentuximab Vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"issue":"S1","key":"10.1016\/j.semradonc.2024.07.013_bib0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/hon.3163_5","article-title":"Nivolumab(N)-AVD improves progressio-free survival compared to Brentuximab Vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL): Results of SWOG S1826","volume":"41","author":"Herrera","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0056","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-Cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0057","first-page":"5","article-title":"Epidemiology of non-Hodgkin's lymphoma","volume":"9","author":"Thandra","year":"2021","journal-title":"Med Sci"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0058","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Cunningham","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0059","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0060","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0061","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"(2011) Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2024.07.013_bib0062","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00066-022-02035-9","article-title":"The new German evidence-based guideline on diffuse large B-cell lymphoma\u2014key aspects for radiation oncologists","volume":"199","author":"Oertel","year":"2023","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0063","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2013.51.4505","article-title":"Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma","volume":"32","author":"Held","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0064","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.ijrobp.2023.06.363","article-title":"Radiotherapy in young, high-risk patients with aggressive B-cell lymphoma: Long-term results from the open-label, randomized, phase 3 R-MegaCHOEP trial","volume":"117","author":"Oertel","year":"2023","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0065","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0066","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1200\/JCO.2017.35.15_suppl.7506","article-title":"Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL","volume":"35","author":"Pfreundschuh","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0067","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1182\/blood.2020005846","article-title":"Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP","volume":"137","author":"Freeman","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0068","unstructured":"NCCN clinical practice guidelines in oncology (NCCN guidelines \u00ae) B-Cell lymphoma version 6.2023"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0069","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14136","article-title":"Guidelines for the management of diffuse large B-cell lymphoma","volume":"174","author":"Chaganti","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0070","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0071","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(08)70078-0","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0072","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00277-010-0964-7","article-title":"Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy","volume":"89","author":"Song","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0073","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ijrobp.2013.02.007","article-title":"Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy","volume":"86","author":"Shi","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0074","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.578865","article-title":"Emerging role of consolidative radiotherapy after complete remission following R-CHOP immunochemotherapy in stage III-IV diffuse large B-Cell lymphoma: A single institutional and case-matched control study","volume":"11","author":"Hong","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0075","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/cncr.29113","article-title":"Radiation for diffuse large B-cell lymphoma in the rituximab era: Analysis of the national comprehensive cancer network lymphoma outcomes project: Radiation After R-CHOP for DLBCL","volume":"121","author":"Dabaja","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0076","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1200\/JCO.2009.27.3441","article-title":"benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy","volume":"28","author":"Phan","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0077","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","article-title":"Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: An open-label, randomised, phase 3 trial (DSHNHL 2002-1)","volume":"13","author":"Schmitz","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0078","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/S2352-3026(21)00022-3","article-title":"Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial","volume":"8","author":"Frontzek","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0079","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s41375-024-02231-9","article-title":"Radiotherapy in younger patients with advanced aggressive B-cell lymphoma \u2013 long-term results from the phase 3 R-MegaCHOEP trial","volume":"38","author":"Oertel","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0080","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijrobp.2019.02.055","article-title":"Phase 2 study of dose-reduced consolidation radiation therapy in diffuse large B-Cell lymphoma","volume":"105","author":"Kelsey","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0081","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0082","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0083","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1200\/JCO.2012.48.0467","article-title":"Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement","volume":"31","author":"Held","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2024.07.013_bib0084","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.semnuclmed.2022.09.001","article-title":"Modern PET-guided radiotherapy planning and treatment for malignant lymphoma","volume":"53","author":"Pepper","year":"2022","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0085","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood-2013-10-530659","article-title":"Primary testicular lymphoma","volume":"123","author":"Cheah","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0086","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO.2010.31.4187","article-title":"First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial","volume":"29","author":"Vitolo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0087","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ajh.20973","article-title":"Consideration of aggressive therapeutic strategies for primary testicular lymphoma","volume":"82","author":"Park","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0088","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0360-3016(01)02647-5","article-title":"Outcome and patterns of failure in testicular lymphoma: A multicenter rare cancer network study","volume":"52","author":"Zouhair","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0089","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2003.11.141","article-title":"Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the international extranodal lymphoma study group","volume":"21","author":"Zucca","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0090","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.ijrobp.2018.01.003","article-title":"Radiation Therapy as an effective salvage strategy for secondary CNS lymphoma","volume":"100","author":"Milgrom","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2024.07.013_bib0091","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/10428194.2020.1821014","article-title":"Consolidative or palliative whole brain radiation for secondary CNS diffuse large B-Cell lymphoma","volume":"62","author":"Walburn","year":"2021","journal-title":"Leuk Lymphoma"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105342962400064X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105342962400064X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T13:59:31Z","timestamp":1734011971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105342962400064X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S105342962400064X"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2024.07.013","relation":{},"ISSN":["1053-4296"],"issn-type":[{"type":"print","value":"1053-4296"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced Stage Hodgkin and Diffuse Large B-Cell Lymphomas: Is There Still a Role for Consolidation Radiotherapy in the PET Era?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2024.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}